[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453989":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":122,"collaborators":26,"id":124,"slug":125,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":26,"eligibilityCriteria":130,"healthyVolunteers":126,"sex":131,"minAge":26,"maxAge":132,"enrollmentInfo":133,"targetDuration":26,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"EyePoint Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DEXYCU (dexamethasoneintraocular suspension) 9%","EXPERIMENTAL","A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.",[13],"Drug: Dexamethasone",{"label":15,"type":16,"description":17,"interventionNames":18},"Prednisolone acetate ophthalmic suspension (USP) 1%","ACTIVE_COMPARATOR","Active treatment control, prednisolone acetate ophthalmic suspension (USP) 1%, four times daily (QID) for 28days, followed by a treatment taper at the investigator's discretion.",[19],"Drug: Prednisolone Acetate Ophthalmic",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexamethasone","single anterior chamber injection",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Prednisolone Acetate Ophthalmic","topical administration four times a day for 28 days, followed by treatment taper",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Ramiro Ribeiro, MD, PhD","CONTACT","833-393-7646","rribeiro@eyepointpharma.com",[38,52,61,71,80,89,98,105,113],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":26},"EyePoint Investigational Site","RECRUITING","Huntington Beach","California","92647","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-117.99923,33.6603,{"lat":50,"lon":49},{"facility":39,"status":53,"city":54,"state":42,"zip":55,"country":44,"countryCode":45,"cosmosGeoPoint":56,"geoPoint":60,"contacts":26},"ACTIVE_NOT_RECRUITING","Palo Alto","94303",{"type":47,"coordinates":57},[58,59],-122.14302,37.44188,{"lat":59,"lon":58},{"facility":62,"status":40,"city":63,"state":64,"zip":65,"country":44,"countryCode":45,"cosmosGeoPoint":66,"geoPoint":70,"contacts":26},"EyePoint Investigative Site","Boston","Massachusetts","02118",{"type":47,"coordinates":67},[68,69],-71.05977,42.35843,{"lat":69,"lon":68},{"facility":39,"status":40,"city":72,"state":73,"zip":74,"country":44,"countryCode":45,"cosmosGeoPoint":75,"geoPoint":79,"contacts":26},"Jackson","Mississippi","39216",{"type":47,"coordinates":76},[77,78],-90.18481,32.29876,{"lat":78,"lon":77},{"facility":39,"status":40,"city":81,"state":82,"zip":83,"country":44,"countryCode":45,"cosmosGeoPoint":84,"geoPoint":88,"contacts":26},"Omaha","Nebraska","68114",{"type":47,"coordinates":85},[86,87],-95.94043,41.25626,{"lat":87,"lon":86},{"facility":39,"status":40,"city":90,"state":91,"zip":92,"country":44,"countryCode":45,"cosmosGeoPoint":93,"geoPoint":97,"contacts":26},"Buffalo","New York","14209",{"type":47,"coordinates":94},[95,96],-78.87837,42.88645,{"lat":96,"lon":95},{"facility":62,"status":40,"city":91,"state":91,"zip":99,"country":44,"countryCode":45,"cosmosGeoPoint":100,"geoPoint":104,"contacts":26},"10032",{"type":47,"coordinates":101},[102,103],-74.00597,40.71427,{"lat":103,"lon":102},{"facility":39,"status":40,"city":106,"state":91,"zip":107,"country":44,"countryCode":45,"cosmosGeoPoint":108,"geoPoint":112,"contacts":26},"Rochester","14642",{"type":47,"coordinates":109},[110,111],-77.61556,43.15478,{"lat":111,"lon":110},{"facility":39,"status":40,"city":114,"state":115,"zip":116,"country":44,"countryCode":45,"cosmosGeoPoint":117,"geoPoint":121,"contacts":26},"Charleston","South Carolina","29425",{"type":47,"coordinates":118},[119,120],-79.93275,32.77632,{"lat":120,"lon":119},{"type":123,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100453989","phase-4-evaluate-the-safety-of-dexycu-for-the-treatment-of-inflammation-following-ocular-surgery-for-childhood-cataract-100453989",false,"NCT05191706","Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract","A Phase 3\u002F4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract","Inclusion Criteria:\n\n* Undergoing uncomplicated cataract surgery with or without a posterior chamber intraocular lens (IOL) implantation.\n* If a contact lens is used for correction of post-operative aphakia, it must be a silicone elastomer lens or a rigid gas permeable lens (no water content).\n* Other protocol-specified inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the investigator.\n* Has a post-traumatic cataract.\n* Presence of active or suspected viral, bacterial, or fungal disease in the study eye.\n* Ocular hypertension with an IOP in the study eye \\>25 mmHg at Screening with or without treatment with anti-glaucoma monotherapy.\n* Subjects who have received a periocular corticosteroid injection in the study eye in the 3 months prior to Screening.\n* Subjects who have received any intravitreal corticosteroid delivery vehicle (eg, Retisert®, Ozurdex®, Iluvien®) in the study eye at any time.\n* Other protocol-specified exclusion criteria may apply","ALL","3 Years",{"count":134,"type":135},60,"ESTIMATED","INTERVENTIONAL",[138],"PHASE4","A Phase 3\u002F4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",[141],"Cataract",[143,144],"pediatric","cataract","2025-04-01",{"date":147,"type":148},"2025-04-03","ACTUAL",{"date":150,"type":148},"2022-01-04",{"date":152,"type":135},"2026-02",{"name":5,"class":6},9]